• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Oral Anticoagulant Edoxaban Alternative for Cancer-Related Thromboembolism

  • in Audio
  • — 26 Jan, 2018
Oral Anticoagulant Edoxaban Alternative for Cancer-Related Thromboembolism
OLYMPUS DIGITAL CAMERA
Oral Anticoagulant Edoxaban Alternative for Cancer-Related Thromboembolism
AudioMedica News
Oral Anticoagulant Edoxaban Alternative for Cancer-Related Thromboembolism
Oral Anticoagulant Edoxaban Alternative for Cancer-Related Thromboembolism
00:00 / 10:00
Apple Podcasts Spotify Stitcher
RSS Feed
Share
Link
Embed
//-->//>' class="input-embed input-embed-3516"/>

Subscribe: Apple Podcasts | Spotify | Stitcher

ATLANTA— In patients with a variety of cancers oral therapy with edoxaban—a direct oral anticoagulant (DOAC)—was just as effective and safe in terms of the risks of recurrent venous thromboembolism (VTE) and bleeding as injections with the low molecular weight heparin (LMWH) dalteparin in the multinational randomized Hokusai VTE-Cancer Study reported at the 2017 American Society of Hematology annual meeting.

LBA-6 A Randomized, Open-Label, Blinded Outcome Assessment Trial Evaluating the Efficacy and Safety of LMWH/Edoxaban Versus Dalteparin for Venous Thromboembolism Associated with Cancer: Hokusai VTE-Cancer Study

“[The] findings show that the edoxaban treatment is non-inferior to the low molecular weight heparin therapy,” said lead author Gary E. Raskob PhD, Dean of the College of Public Health and Professor of Medicine and Epidemiology at the University of Oklahoma in Oklahoma City.

READ MORE from the American Society of Hematology Meeting in Oncology Times.

 

You may also like...

  • Cabozantinib Better for VEGF Resistant Metastatic Renal Cell Carcinoma Cabozantinib Better for VEGF Resistant Metastatic Renal Cell Carcinoma 20 Apr, 2017
  • Gender Disparity in Head and Neck Cancer Treatment and Outcomes Gender Disparity in Head and Neck Cancer Treatment and Outcomes 9 Jun, 2018
  • Active Surveillance Better for Which Renal Cell Cancers? Active Surveillance Better for Which Renal Cell Cancers? 17 Apr, 2017
  • Early Lung Cancer Responds to Preoperative Nivolumab Early Lung Cancer Responds to Preoperative Nivolumab 17 Nov, 2016

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story Venetoclax Pro-Apoptotic Therapy Benefits Older Patients with Acute Myeloid Leukemia
  • Next story Randomized Study Confirms Rivaroxaban Oral Alternative For Cancer Thromboembolism
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Randomized Study Confirms Rivaroxaban Oral…
    • Microbiome Diversity Key To Survival After…
    • Ibrutinib: New Frontline Standard for Chronic…
    • Polygenic Risk Scores Could Help Predict Second…
    • New Front Line Standard for Older Patients with…
  • Home
  • Audio
  • Oral Anticoagulant Edoxaban Alternative for Cancer-Related Thromboembolism

© COPYRIGHT 2020 AUDIOMEDICA.COM.